|
4 Companies |
|
2 Products |
|
2 Products |
|
4 Mechanisms of Action |
|
0 Trials |
|
31 News |
|
- | Enrollment change, Trial completion date, Trial primary completion date: Bi-Level Positive Airway Ventilation for Acute Chest Syndrome (clinicaltrials.gov) - Dec 11, 2018
P=N/A, N=3, Terminated, Sponsor: Albert Einstein College of Medicine, Inc.
N=60 --> 3 | Trial completion date: Jul 2014 --> Sep 2016 | Trial primary completion date: Jul 2014 --> Sep 2016
- | azithromycin / Generic mfg.
Enrollment change, Trial withdrawal, Trial primary completion date: A Pilot Study of Azithromycin Prophylaxis for Acute Chest Syndrome in Sickle Cell Disease (clinicaltrials.gov) - Jun 21, 2018
P1, N=0, Withdrawn, Sponsor: University of Mississippi Medical Center
N=60 --> 3 | Trial completion date: Jul 2014 --> Sep 2016 | Trial primary completion date: Jul 2014 --> Sep 2016 N=15 --> 0 | Recruiting --> Withdrawn | Trial primary completion date: Dec 2018 --> Dec 2017
- | morphine sulphate / Generic mfg.
Trial completion: Choosing Opioid Management for Pain and Analyzing Acute Chest Syndrome (ACS) Rates Equally (clinicaltrials.gov) - Feb 20, 2018
P3, N=40, Completed, Sponsor: Children's Healthcare of Atlanta
N=15 --> 0 | Recruiting --> Withdrawn | Trial primary completion date: Dec 2018 --> Dec 2017 Active, not recruiting --> Completed
- | budesonide inhalation suspension / Generic mfg.
Trial completion, Enrollment change: Inhaled Corticosteroid Use to Prevent Acute Chest Syndrome Recurrence in Children Between 1 and 4 With Sickle Cell Disease: a Feasibility Trial (clinicaltrials.gov) - Feb 17, 2017
P1, N=36, Completed, Sponsor: Vanderbilt University
Active, not recruiting --> Completed Active, not recruiting --> Completed | N=30 --> 36
- Trial completion, Enrollment change, Trial primary completion date: Role of Placenta Growth Factor in Sickle Acute Chest Syndrome (clinicaltrials.gov) - Nov 15, 2016
P=N/A, N=136, Completed, Sponsor: Children's Hospital Medical Center, Cincinnati
Active, not recruiting --> Completed | N=30 --> 36 Active, not recruiting --> Completed | N=175 --> 136 | Trial primary completion date: Dec 2016 --> Dec 2012
- budesonide inhalation suspension / Generic mfg.
Enrollment closed, Enrollment change, Trial primary completion date: Inhaled Corticosteroid Use to Prevent Acute Chest Syndrome Recurrence in Children Between 1 and 4 With Sickle Cell Disease: a Feasibility Trial (clinicaltrials.gov) - Nov 8, 2016
P1, N=30, Active, not recruiting, Sponsor: Vanderbilt University
Active, not recruiting --> Completed | N=175 --> 136 | Trial primary completion date: Dec 2016 --> Dec 2012 Recruiting --> Active, not recruiting | N=20 --> 30 | Trial primary completion date: Sep 2016 --> Dec 2016
- Trial primary completion date: Role of Placenta Growth Factor in Sickle Acute Chest Syndrome (clinicaltrials.gov) - Jan 27, 2016
P=N/A, N=175, Active, not recruiting, Sponsor: Children's Hospital Medical Center, Cincinnati
Recruiting --> Active, not recruiting | N=20 --> 30 | Trial primary completion date: Sep 2016 --> Dec 2016 Trial primary completion date: Dec 2015 --> Dec 2016
- Trial completion, Enrollment change: ST Elevation in Acute Chest Pain; Could Measurement of Lipoprotein-associated Phospholipase A2 (Lp-PLA2) be Helpful to the Clinician? (clinicaltrials.gov) - Dec 15, 2015
P=N/A, N=40, Completed, Sponsor: Alexhander Izhaki
Trial primary completion date: Dec 2015 --> Dec 2016 Recruiting --> Completed | N=100 --> 40
- azithromycin / Generic mfg.
New P1 trial: A Pilot Study of Azithromycin Prophylaxis for Acute Chest Syndrome in Sickle Cell Disease (clinicaltrials.gov) - Dec 15, 2015
P1, N=15, Recruiting, Sponsor: University of Mississippi Medical Center
- budesonide inhalation suspension / Generic mfg.
Trial primary completion date: Inhaled Corticosteroid Use to Prevent Acute Chest Syndrome Recurrence in Children Between 1 and 4 With Sickle Cell Disease: a Feasibility Trial (clinicaltrials.gov) - Apr 18, 2015
P1, N=20, Recruiting, Sponsor: Vanderbilt University
Recruiting --> Completed | N=100 --> 40 Trial primary completion date: Nov 2015 --> Sep 2016
- Enrollment change: VPACS: Non Invasive Positive Pressure Ventilation for Prevention of Acute Chest Syndrome in Sickle Cell Disease (clinicaltrials.gov) - Apr 10, 2015
P=N/A, N=6, Terminated, Sponsor: Assistance Publique - H
Trial primary completion date: Nov 2015 --> Sep 2016 N=120 --> 6
- Trial completion, Trial completion date: Arginine Treatment of Acute Chest Syndrome (Pneumonia) in Sickle Cell Disease Patients (clinicaltrials.gov) - Mar 25, 2015
P2, N=30, Completed, Sponsor: Children's Hospital & Research Center Oakland
N=120 --> 6 Recruiting --> Completed | Trial completion date: Jul 2004 --> Jul 2005
- morphine sulphate / Generic mfg.
Enrollment change: Choosing Opioid Management for Pain and Analyzing Acute Chest Syndrome (ACS) Rates Equally (clinicaltrials.gov) - Feb 19, 2015
P3, N=40, Active, not recruiting, Sponsor: Children's Healthcare of Atlanta
Recruiting --> Completed | Trial completion date: Jul 2004 --> Jul 2005 N=250 --> 40
- Trial completion, Enrollment change: Quantifying the Presence of Lung Disease and Pulmonary Hypertension in Children With Sickle Cell Disease (clinicaltrials.gov) - Dec 5, 2014
P1, N=5, Completed, Sponsor: Duke University
N=250 --> 40 Recruiting --> Completed | N=32 --> 5
- | Inomax (nitric oxide) / Mallinckrodt
Trial completion, Enrollment change: INNOSTAPED: Nitric Oxide Therapy for Acute Chest Syndrome in Sickle Cell Disease Children (clinicaltrials.gov) - Dec 5, 2014
P2, N=21, Completed, Sponsor: Assistance Publique - H
Recruiting --> Completed | N=32 --> 5 Recruiting --> Completed | N=50 --> 21
- | morphine sulphate / Generic mfg.
Enrollment closed, Trial primary completion date: Choosing Opioid Management for Pain and Analyzing Acute Chest Syndrome (ACS) Rates Equally (clinicaltrials.gov) - Nov 25, 2014
P3, N=250, Active, not recruiting, Sponsor: Children's Healthcare of Atlanta
Recruiting --> Completed | N=50 --> 21 Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2014 --> Jan 2014
- budesonide inhalation suspension / Generic mfg.
New P1 trial: Inhaled Corticosteroid Use to Prevent Acute Chest Syndrome Recurrence in Children Between 1 and 4 With Sickle Cell Disease: a Feasibility Trial (clinicaltrials.gov) - Jul 12, 2014
P1, N=20, Recruiting, Sponsor: Vanderbilt University
- Enrollment open: Quantifying the Presence of Lung Disease and Pulmonary Hypertension in Children With Sickle Cell Disease (clinicaltrials.gov) - Apr 7, 2014
P1, N=32, Recruiting, Sponsor: Duke University
Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2014 --> Jan 2014 Not yet recruiting --> Recruiting
- ||||| Enrollment change: Effect of Inhaled Nitric Oxide in Acute Chest Syndrome (INOSTA Study) (clinicaltrials.gov) - Jul 31, 2013
P2/3, N=100, Completed, Sponsor: Assistance Publique - H
Not yet recruiting --> Recruiting N=260 --> 100
- ||||||| Trial completion: Effect of Inhaled Nitric Oxide in Acute Chest Syndrome (INOSTA Study) (clinicaltrials.gov) - Jul 31, 2013
P2/3, N=100, Completed, Sponsor: Assistance Publique - H
N=260 --> 100 Recruiting --> Completed
- New P1 trial: Quantifying the Presence of Lung Disease and Pulmonary Hypertension in Children With Sickle Cell Disease (clinicaltrials.gov) - Jul 9, 2013
P1, N=32, Recruiting, Sponsor: Duke University
- Trial termination: VPACS: Non Invasive Positive Pressure Ventilation for Prevention of Acute Chest Syndrome in Sickle Cell Disease (clinicaltrials.gov) - Jun 3, 2013
P=N/A, N=120, Terminated, Sponsor: Assistance Publique - H
Recruiting --> Completed Recruiting --> Terminated; decision of the promoter
- Enrollment change: Preventing Acute Chest Syndrome by Transfusion Feasibility Study (clinicaltrials.gov) - Feb 21, 2013
P=N/A, N=237, Completed, Sponsor: New England Research Institutes
Recruiting --> Terminated; decision of the promoter N=40 --> 237
- Clinical: Bi-Level Positive Airway Ventilation for Acute Chest Syndrome (clinicaltrials.gov) - Apr 29, 2012
P=N/A, N=60, Not yet recruiting, Sponsor: Albert Einstein College of Medicine of Yeshiva University
- varespladib (A-002) / Anthera Pharma, Ophirex
Trial termination: IMPACTS-2: A Study of Varespladib Infusion in Subjects With Sickle Cell Disease. (clinicaltrials.gov) - Mar 20, 2012
P2, N=2, Terminated, Sponsor: Anthera Pharmaceuticals
N=40 --> 237 Not yet recruiting --> Terminated; change in company plans
- varespladib (A-002) / Anthera Pharma, Ophirex
Enrollment change: IMPACTS-2: A Study of Varespladib Infusion in Subjects With Sickle Cell Disease. (clinicaltrials.gov) - Mar 20, 2012
P2, N=2, Terminated, Sponsor: Anthera Pharmaceuticals
Not yet recruiting --> Terminated; change in company plans N=150 --> 2
- varespladib (A-002) / Anthera Pharma, Ophirex
New P2 trial: IMPACTS-2: A Study of Varespladib Infusion in Subjects With Sickle Cell Disease. (clinicaltrials.gov) - Jan 29, 2012
P2, N=2, Terminated, Sponsor: Anthera Pharmaceuticals
- | varespladib (A-002) / Anthera Pharma, Ophirex
Enrollment change: IMPACTS Trial: Investigation of the Modulation of Phospholipase in Acute Chest Syndrome (clinicaltrials.gov) - Jan 17, 2012
P2, N=30, Completed, Sponsor: Anthera Pharmaceuticals
N=150 --> 2 N=60 --> 30
- Enrollment open: ST Elevation in Acute Chest Pain; Could Measurement of Lipoprotein-associated Phospholipase A2 (Lp-PLA2) be Helpful to the Clinician? (clinicaltrials.gov) - Aug 15, 2011
P=N/A, N=100, Recruiting, Sponsor: Wolfson Medical Center
N=60 --> 30 Not yet recruiting --> Recruiting